Overview

The CHORAL Flow Study

Status:
Recruiting
Trial end date:
2022-05-27
Target enrollment:
Participant gender:
Summary
CHORAL Flow is a randomised, double blinded, placebo-controlled trial of the effects of evolocumab on coronary flow at 12 weeks.
Phase:
Phase 4
Details
Lead Sponsor:
Imperial College London
Treatments:
Antibodies, Monoclonal
Evolocumab